Movement Alert｜Cencora Rises 3.25% in Pre-Market Trading, Multiple Catalysts Including Analyst Upgrade and Buyback Resumption

Market Focus07-17

On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.

On the news front, Evercore ISI raised its price target on Cencora to $330 from $300 on July 7, maintaining an Outperform rating. The analyst consensus mean target stands at $353.50 according to FactSet. Additionally, Chairman Mark Durcan purchased 4,000 shares at $266 apiece for approximately $1 million — his largest transaction during his board tenure, described as an unusually large insider buy following the stock's decline after Q2 earnings. The company also announced resumption of its share repurchase program with authorization of up to $2 billion after pausing it in January. Furthermore, Cencora signed a distribution agreement with Gilead's Kite unit to support FDA-approved CAR-T cell therapies Yescarta and Tecartus in the U.S. market, expanding its specialty pharmaceutical distribution capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127770687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127770687","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Cencora Rises 3.25% in Pre-Market Trading, Multiple Catalysts Including Analyst Upgrade and Buyback Resumption","media":"Market Focus","content":"<p><p>On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.</p><p>On the news front, Evercore ISI raised its price target on Cencora to $330 from $300 on July 7, maintaining an Outperform rating. The analyst consensus mean target stands at $353.50 according to FactSet. Additionally, Chairman Mark Durcan purchased 4,000 shares at $266 apiece for approximately $1 million — his largest transaction during his board tenure, described as an unusually large insider buy following the stock's decline after Q2 earnings. The company also announced resumption of its share repurchase program with authorization of up to $2 billion after pausing it in January. Furthermore, Cencora signed a distribution agreement with Gilead's Kite unit to support FDA-approved CAR-T cell therapies Yescarta and Tecartus in the U.S. market, expanding its specialty pharmaceutical distribution capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Cencora Rises 3.25% in Pre-Market Trading, Multiple Catalysts Including Analyst Upgrade and Buyback Resumption</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Cencora Rises 3.25% in Pre-Market Trading, Multiple Catalysts Including Analyst Upgrade and Buyback Resumption\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.</p><p>On the news front, Evercore ISI raised its price target on Cencora to $330 from $300 on July 7, maintaining an Outperform rating. The analyst consensus mean target stands at $353.50 according to FactSet. Additionally, Chairman Mark Durcan purchased 4,000 shares at $266 apiece for approximately $1 million — his largest transaction during his board tenure, described as an unusually large insider buy following the stock's decline after Q2 earnings. The company also announced resumption of its share repurchase program with authorization of up to $2 billion after pausing it in January. Furthermore, Cencora signed a distribution agreement with Gilead's Kite unit to support FDA-approved CAR-T cell therapies Yescarta and Tecartus in the U.S. market, expanding its specialty pharmaceutical distribution capabilities.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COR","symbol_name":"CENCORA","start_time":0,"source_url":"","article_id":"1127770687","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127770687","pubTimestamp":1784294393,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.On the news front, Evercore...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COR":"CENCORA"},"translate_title":"走势警报|Cencora 在盘前交易中上涨 3.25%，多重催化剂包括分析师升级和回购恢复","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":1},"content_text":"On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.On the news front, Evercore ISI raised its price target on Cencora to $330 from $300 on July 7, maintaining an Outperform rating. The analyst consensus mean target stands at $353.50 according to FactSet. Additionally, Chairman Mark Durcan purchased 4,000 shares at $266 apiece for approximately $1 million — his largest transaction during his board tenure, described as an unusually large insider buy following the stock's decline after Q2 earnings. The company also announced resumption of its share repurchase program with authorization of up to $2 billion after pausing it in January. Furthermore, Cencora signed a distribution agreement with Gilead's Kite unit to support FDA-approved CAR-T cell therapies Yescarta and Tecartus in the U.S. market, expanding its specialty pharmaceutical distribution capabilities.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127770687","isCrawlerRequest":true}